MNMD

Mind Medicine MindMed Inc
3.48
0.10 (2.96%)
Upgrade to Real-Time
Regular Market
3.48
Volume 341,251
Bid Price 3.47
Ask Price 3.49
News -
Day High 3.5801

Low
2.12

52 Week Range

High
22.20

Day Low 3.36
Company Name Stock Ticker Symbol Market Type
Mind Medicine MindMed Inc MNMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.10 2.96% 3.48 14:06:53
Open Price Low Price High Price Close Price Prev Close
3.42 3.36 3.5801 3.38
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,104 341,251 $ 3.51 $ 1,198,645 - 2.12 - 22.20
Last Trade Time Type Quantity Stock Price Currency
14:06:07 100 $ 3.48 USD

Period:

Draw Mode:

Mind Medicine MindMed Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 130.75M 37.57M 37.28M $ - $ - - -1.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -8.68k 17.80%

more financials information »

Mind Medicine MindMed News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MNMD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.423.623.093.38488,1300.061.75%
1 Month2.603.772.5313.28624,6870.8833.85%
3 Months2.573.772.122.87595,2550.9135.41%
6 Months10.5019.952.1212.104,733,239-7.02-66.86%
1 Year16.597522.202.1212.863,852,190-13.12-79.03%
3 Years86.5586.552.1230.174,890,262-83.07-95.98%
5 Years86.5586.552.1230.174,890,262-83.07-95.98%

Mind Medicine MindMed Description

Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.